Clinical Trials for Uterine Cancer

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable solid tumors (excluding NSCLC) harboring activating HER2 mutations, who have progressed on standard therapy or have no satisfactory alternatives. Patients receive BAY2927088, an oral reversible tyrosine kinase inhibitor targeting mutant HER2 and EGFR.

ClinicalTrials.gov ID: NCT06760819

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling adult women with advanced or recurrent endometrioid endometrial cancer (including mixed if >50% endometrioid) or select non-endometrioid tumors harboring activating Wnt/β-catenin mutations, excluding prior PD-1/PD-L1 or anti-DKK1 therapy and dMMR/MSI-H disease. Participants receive pembrolizumab plus DKN-01 (sirexatamab), a monoclonal antibody that neutralizes DKK1 to modulate Wnt/β-catenin and CKAP4/PI3K–AKT signaling, aiming to enhance response to PD-1 inhibition.

ClinicalTrials.gov ID: NCT05761951

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with recurrent or metastatic cervical squamous/adenocarcinoma after exactly one prior platinum doublet (±bevacizumab) and prior PD-1/PD-L1 therapy, ECOG 0–1, and measurable disease are randomized to sacituzumab tirumotecan (TROP2-directed ADC with topoisomerase I payload) versus physician’s choice of single-agent chemotherapy (pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, or irinotecan). Primary efficacy focuses on overall survival in TROP2-high and all-comer populations.

ClinicalTrials.gov ID: NCT06459180

A Randomized, Open-label, Two-arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy in Patients With Recurrent or Metastatic Cervical Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with PD-L1–positive, HPV16/18-positive recurrent or metastatic cervical cancer who have progressed on prior pembrolizumab (≤2 prior systemic regimens) are randomized to pembrolizumab alone versus pembrolizumab plus PRGN-2009, an investigational gorilla adenoviral therapeutic vaccine targeting HPV16/18 E6/E7 to enhance HPV-specific T-cell responses. Key endpoints include ORR, with additional safety and survival outcomes; notable exclusions include active CNS disease and other active malignancies.

ClinicalTrials.gov ID: NCT06157151

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with HER2 IHC 3+/2+, pMMR primary advanced or recurrent endometrial carcinoma (systemic therapy–naïve in the advanced/recurrent setting; carcinosarcoma allowed) are randomized to T-DXd plus rilvegostomig (bispecific PD-1/TIGIT antibody) or T-DXd plus pembrolizumab versus carboplatin/paclitaxel plus pembrolizumab, with PFS as the primary endpoint. T-DXd is an anti-HER2 antibody–drug conjugate delivering a topoisomerase I inhibitor (DXd); key exclusions include prior ICIs/ADCs and significant ILD/pneumonitis risk.

ClinicalTrials.gov ID: NCT06989112

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced/metastatic solid tumors in three cohorts: recurrent/metastatic cervical cancer after 1–2 prior lines; recurrent/metastatic HNSCC (including PD-L1–positive, systemic-therapy–naive or platinum-refractory); and untreated R/M HNSCC receive volrustomig, a bispecific PD-1/CTLA-4 antibody, as monotherapy or combined with chemo (carboplatin/paclitaxel or 5-FU plus platinum). Excludes prior checkpoint inhibitor exposure and requires ECOG 0–1 and PD-L1 testing; endpoints include ORR and safety per RECIST 1.1.

ClinicalTrials.gov ID: NCT06535607

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study for adults with untreated recurrent, persistent, or metastatic cervical cancer (squamous, adeno, or adenosquamous) not amenable to curative therapy, ECOG 0–1, and no prior checkpoint inhibitor or systemic therapy for metastatic disease. Patients receive induction lorigerlimab (MGD019), a bispecific PD-1/CTLA-4 checkpoint inhibitor (DART IgG4) given IV every 3 weeks, with efficacy assessed by RECIST and close safety monitoring for immune-related AEs.

ClinicalTrials.gov ID: NCT05475171

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling adults with platinum‑resistant high‑grade serous ovarian/primary peritoneal/fallopian tube cancer or clear cell gynecologic cancers (ovarian, endometrial, vaginal, vulvar, cervical) with measurable disease after prior lines of therapy; excludes prior PD‑1/PD‑L1/PD‑L2 or CTLA‑4 exposure and platinum‑refractory disease. Patients receive lorigerlimab (MGD019), an investigational bispecific checkpoint inhibitor targeting PD‑1 and CTLA‑4, given IV every 21 days until progression or intolerance.

ClinicalTrials.gov ID: NCT06730347

A Phase 2 Study of Ivonescimab (Bispecific Antibody Against PD1 and VEGF) For the Treatment of Endometrial (EC) and Cervical (CC) Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study of ivonescimab, a tetravalent bispecific antibody targeting PD‑1 and VEGF, in adults with metastatic or recurrent endometrial or cervical cancer that has progressed after at least one platinum regimen; prior PD‑1 or VEGF therapy allowed, ECOG 0–2, measurable disease required. Ivonescimab is given IV every 3 weeks for up to 24 months, aiming to combine immune checkpoint blockade with anti‑angiogenesis; primary endpoint is RECIST ORR.

ClinicalTrials.gov ID: NCT06925724

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced or recurrent endometrioid endometrial carcinoma harboring a PI3K/AKT/mTOR pathway alteration, post 1–4 prior regimens including platinum and typically a checkpoint inhibitor, receive sapanisertib (mTORC1/2 inhibitor) plus serabelisib (PI3Kα inhibitor) combined with paclitaxel; a substudy adds an insulin‑suppressing diet. Key exclusions include uncontrolled CNS disease, significant cardiac issues, CYP3A modulator use, gastric pH–raising meds, QTc >480 ms, and poorly controlled diabetes or insulin use.

ClinicalTrials.gov ID: NCT06463028